Cercar
01/03/2022
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)
Podzamczer, D, Mican, R, Tiraboschi, J, Portilla, J, Domingo, P, Llibre, JM, Ribera, E, Vivancos, MJ, Morano, L, Masia, M, Gomez, C, Fanjul, F, Payeras, A, Inciarte, A, Estrada, V, Rivero, A, Castro, A, Bernal, E, Vinuesa, D, Knobel, H, Troya, J, Macias, J, Montero, M, Sanz, J, Navarro-Alcaraz, A, Caicedo, A, Fernandez, G, Martinez, E, Moreno, S. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57). Open Forum Infectious Diseases. 2022; 9(3)DOI:10.1093/ofid/ofab595. PMID:35237700. IF:4.200(Q2/4D).
01/03/2022
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
Garcia-Alfonso, P, Saiz-Rodriguez, M, Mondejar, R, Salazar, J, Paez, D, Borobia, AM, Safont, MJ, Garcia-Garcia, I, Colomer, R, Garcia-Gonzalez, X, Herrero, MJ, Lopez-Fernandez, LA, Abad-Santos, F. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. Clinical & Translational Oncology. 2022; 24(3)DOI:10.1007/s12094-021-02708-4. PMID:34773566. IF:3.400(Q3/6D).
01/03/2022
PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence
Eggermont, AMM, Ascierto, PA, Khushalani, NI, Schadendorf, D, Boland, G, Weber, J, Lewis, KD, Johnson, D, Rivalland, G, Khattak, A, Majem, M, Gogas, H, Long, GV, Currie, SL, Chien, D, Tagliaferri, MA, Carlino, MS, Diab, A. PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Future Oncology. 2022; 18(8)DOI:10.2217/fon-2021-1286. PMID:35073733. IF:3.300(Q3/6D).
01/03/2022
Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome
Sanchez, A, Roos, VH, Navarro, M, Pineda, M, Caballol, B, Moreno, L, Carballal, S, Rodriguez-Alonso, L, Cajal, TRY, Llort, G, Pinol, V, Lopez-Fernandez, A, Salces, I, Pico, MD, Rivas, L, Bujanda, L, Garzon, M, Pizarro, A, de Castro, EM, Lopez-Arias, MJ, Poves, C, Garau, C, Rodriguez-Alcalde, D, Herraiz, M, Alvarez-Urrutia, C, Dacal, A, Carrillo-Palau, M, Cid, L, Ponce, M, Barreiro-Alonso, E, Saperas, E, Aguirre, E, Romero, C, Bastiaansen, B, Gonzalez-Acosta, M, Morales-Romero, B, Ocana, T, Rivero-Sanchez, L, Jung, G, Bessa, X, Cubiella, J, Jover, R, Rodriguez-Moranta, F, Balmana, J, Brunet, J, Castells, A, Dekker, E, Capella, G, Serra-Burriel, M, Moreira, L, Pellise, M, Balaguer, F. Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome. Clinical Gastroenterology and Hepatology. 2022; 20(3)DOI:10.1016/j.cgh.2020.11.002. PMID:33157315. IF:12.600(Q1/1D).